Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Breast Cancer Guideline Updates 2024 : Episode 7
Exploring Biomarker Testing and Personalized Treatments in Breast Cancer
William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and anticipates the growing influence of personalized medicine on the future of breast cancer treatment.
EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer
EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024
EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs
EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib
EP: 6.Exploring Results from CAPItello-291 Trial
Now Viewing
EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer
EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook
EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts
- What are the current guidelines for testing for targetable mutations in breast cancer, and how widely are they followed in clinical practice? How can biomarker testing for targetable mutations, such as PIK3CA or AKT1, be improved or streamlined?
- How accessible are these biomarker tests in community oncology?
- How is personalized medicine expected to impact the future use of targeted therapies (such as the PI3K pathway inhibitors) in breast cancer? What developments are needed to fully realize its potential?
Related Videos
Related Content
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025Article
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
